Daily non-political popular news in brief.
Mass. General leading international trial of novel breast cancer drug
12-13-2006 · EurekAlert!A clinical trial of a new targeted breast cancer drug, led by physicians at Massachusetts General Hospital Cancer Center, has begun enrolling patients. The TEACH (Tykerb Evaluation After CHemotherapy) trial will investigate the experimental drug Tykerb (lapatinib) in patients with early-stage, HER2-positive breast cancer who have not been treated with Herceptin, another targeted drug used for the same type of tumor.
Read more »
Keywords: mass, general, leading, international, trial, novel, breast, cancer, drug
« Previous | Next »
Similar news on "Mass. General leading international trial of novel breast cancer drug":
- Drug-based on MGH discovery may significantly improve treatment of dangerous blood disorder
01-31-2008 · EurekAlert!
Two clinical trials of the novel drug romiplostim show that it significantly improved platelet levels in patients with chronic immune thrombocytopenic purpura, a hematologic disorder that can cause uncontrolled bleeding. An international research team reports Phase 3 trial results for the drug, which duplicates the action of a natural hormone discovered by a Massachusetts General Hospital investigator, in the Feb. 2 issue of The Lancet.
Similar news · Read more »
- Experimental cancer pharmaceuticals under trial
10-23-2007 · EurekAlert!
Advances in drug development have enabled scientists to attack new and unconventional cancer targets, leading to better treatments for cancer patients with fewer unwanted side effects. The following items highlight the early results from two experimental therapeutics, currently involved in Phase I or II trials, which are being presented today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
Similar news · Read more »
- Drug based on MGH discovery may significantly improve treatment of dangerous blood disorder
01-31-2008 · EurekAlert!
Two clinical trials of the novel drug romiplostim show that it significantly improved platelet levels in patients with chronic immune thrombocytopenic purpura, a hematologic disorder that can cause uncontrolled bleeding. An international research team reports Phase 3 trial results for the drug, which duplicates the action of a natural hormone discovered by a Massachusetts General Hospital investigator, in the Feb. 2 issue of the Lancet.
Similar news · Read more »
- Molecular signature may identify cisplatin-sensitive breast tumors
04-19-2007 · EurekAlert!
Researchers at the Massachusetts General Hospital Cancer Center have identified a subgroup of hard-to-treat breast cancers that may be sensitive to the drug cisplatin, rarely used in the treatment of breast tumors. They also have discovered the molecular basis of this sensitivity, which may help identify patients most likely to benefit from cisplatin treatment.
Similar news · Read more »
- New angiogenesis inhibitor has promise for treating deadly brain tumor
01-16-2007 · EurekAlert!
Researchers from the Massachusetts General Hospital Cancer Center have found that AZD2171, a new angiogenesis inhibitor, can significantly reduce the size of the deadly brain tumors called glioblastomas and has the potential of improving the effectiveness of other therapeutic techniques. The Phase 2 clinical trial also finds that the new drug can alleviate brain swelling (edema), a debilitating symptom in many brain cancer patients that currently can be treated only with steroid drugs.
Similar news · Read more »
- A new computational technique predicts side-effects of a major cancer drug
11-27-2007 · EurekAlert!
Researchers at the University of California San Diego have developed a novel computer technique to search for the side effects of major pharmaceuticals. The study, reported Nov. 30 in PLoS Computational Biology, relates to a class of drugs known as Select Estrogen Receptor Modulators, which includes tamoxifen, the most prescribed drug in the treatment of breast cancer.
Similar news · Read more »
- New approaches to the diagnosis of oral cancer
03-23-2007 · EurekAlert!
Oral cancer is diagnosed in more than 30,000 individuals in the US annually, claiming 10,000 lives each year. Early detection remains the best way to ensure patient survival and quality of life. Today, during the 85th General Session of the International Association for Dental Research, scientists from the University of California-Irvine present two novel, non-invasive, ultra-fast imaging approaches to oral cancer detection, diagnostic screening and mapping.
Similar news · Read more »
- Latest drugs improve survival for metastatic breast cancer
07-23-2007 · EurekAlert!
Newer drug therapies available since the 1990s, in particular aromatase inhibitors, improve the survival of women with metastatic breast cancer in the general population, according to a new study.
Similar news · Read more »
- Breast cancer survival rates improved by novel drug sequence, say researchers
02-12-2007 · EurekAlert!
Changing the way women are treated for breast cancer could improve their overall chance of survival, according to research published today in the Lancet. The new paper shows that switching to a drug called exemestane, two to three years after commencing standard therapy with the drug tamoxifen, can cut the risk of death for certain women by a further 17 percent compared with using tamoxifen alone.
Similar news · Read more »
- Drug shows activity against brain metastases
06-03-2007 · EurekAlert!
The drug lapatinib shrank tumors and slowed progression of brain metastases in some patients with advanced breast cancer, according to results of a clinical trial being presented by Dana-Farber Cancer Institute scientists at the annual meeting of the American Society of Clinical Oncology.
Similar news · Read more »
